New HIV vaccine combo enters human safety trials

NCT ID NCT06205056

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: U.S. Army Medical Research and Development Command Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether a new HIV vaccine combination is safe and can trigger an immune response. About 78 healthy adults will receive either the vaccine or a placebo. The study uses two different dosing schedules to see which works better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HIV vaccine combination (Ad26.Mos4.HIV and CH505 TF chTrimer + ALFQ)
What this could lead to: If successful, this could help develop a vaccine that trains the immune system to fight HIV.
What could go wrong: This is an early Phase 1 trial focused on safety, not effectiveness. The vaccine may not produce a strong immune response or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HUMAN IMMUNODEFICIENCY VIRUS

Contacts and locations

Locations

Makerere University Walter Reed Project (MUWRP)
RECRUITING

Kampala, Uganda

More trials for these conditions

Other studies related to the condition(s) this trial covers.